Publication: Moving beyond vegf for anti-angiogenesis strategies in gynecologic cancer
Issued Date
2012-01-01
Resource Type
ISSN
18734286
13816128
13816128
Other identifier(s)
2-s2.0-84862528348
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Pharmaceutical Design. Vol.18, No.19 (2012), 2713-2719
Suggested Citation
Duangmani Thanapprapasr, Wei Hu, Anil K. Sood, Robert L. Coleman Moving beyond vegf for anti-angiogenesis strategies in gynecologic cancer. Current Pharmaceutical Design. Vol.18, No.19 (2012), 2713-2719. doi:10.2174/138161212800626201 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15184
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Moving beyond vegf for anti-angiogenesis strategies in gynecologic cancer
Other Contributor(s)
Abstract
Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development. © 2012 Bentham Science Publishers.